SG11202007922XA - Methods for prostate cancer detection and treatment - Google Patents

Methods for prostate cancer detection and treatment

Info

Publication number
SG11202007922XA
SG11202007922XA SG11202007922XA SG11202007922XA SG11202007922XA SG 11202007922X A SG11202007922X A SG 11202007922XA SG 11202007922X A SG11202007922X A SG 11202007922XA SG 11202007922X A SG11202007922X A SG 11202007922XA SG 11202007922X A SG11202007922X A SG 11202007922XA
Authority
SG
Singapore
Prior art keywords
treatment
methods
prostate cancer
cancer detection
detection
Prior art date
Application number
SG11202007922XA
Inventor
Mark Kidd
Ignat Drozdov
Irvin Mark Modlin
Original Assignee
Liquid Biopsy Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Res Llc filed Critical Liquid Biopsy Res Llc
Publication of SG11202007922XA publication Critical patent/SG11202007922XA/en

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202007922XA 2018-02-22 2019-02-21 Methods for prostate cancer detection and treatment SG11202007922XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862633675P 2018-02-22 2018-02-22
PCT/US2019/018878 WO2019165021A1 (en) 2018-02-22 2019-02-21 Methods for prostate cancer detection and treatment

Publications (1)

Publication Number Publication Date
SG11202007922XA true SG11202007922XA (en) 2020-09-29

Family

ID=65686083

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007922XA SG11202007922XA (en) 2018-02-22 2019-02-21 Methods for prostate cancer detection and treatment

Country Status (12)

Country Link
US (2) US11410748B2 (en)
EP (1) EP3755816A1 (en)
JP (1) JP2021514624A (en)
KR (1) KR20200123450A (en)
CN (1) CN112673115A (en)
AU (1) AU2019224025A1 (en)
BR (1) BR112020016989A2 (en)
CA (1) CA3091647A1 (en)
IL (1) IL276748A (en)
MX (1) MX2020008702A (en)
SG (1) SG11202007922XA (en)
WO (1) WO2019165021A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901819A (en) 2019-10-10 2022-08-12 液体活检研究有限责任公司 Compositions, methods and kits for biological sample and RNA stabilization
IL295356A (en) * 2020-02-06 2022-10-01 Oncohost Ltd Machine learning prediction of therapy response
EP4385024A1 (en) 2021-08-11 2024-06-19 Oncohost Ltd Predicting patient response
WO2024081796A1 (en) * 2022-10-12 2024-04-18 Liquid Biopsy Research LLC Methods for prostate cancer detection in saliva
GB2623570A (en) * 2022-10-21 2024-04-24 Wobble Genomics Ltd Method and products for biomarker identification
CN116908444B (en) * 2023-09-13 2023-12-19 中国医学科学院北京协和医院 Application of plasma MAX autoantibody in prognosis prediction of advanced non-small cell lung cancer PD-1 monoclonal antibody combined chemotherapy treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
CA2804626C (en) * 2010-07-27 2020-07-28 Genomic Health, Inc. Method for using expression of glutathione s-transferase mu 2 (gstm2) to determine prognosis of prostate cancer
MX366164B (en) * 2012-01-31 2019-07-01 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer.
EP2875157A4 (en) * 2012-07-20 2016-10-26 Diagnocure Inc Methods, kits and compositions for providing a clinical assessment of prostate cancer
EP2882869A4 (en) * 2012-08-07 2016-04-20 Jackson H M Found Military Med Prostate cancer gene expression profiles
SG11201510210XA (en) * 2013-06-13 2016-01-28 Univ South Australia Methods for detecting prostate cancer
RU2668164C2 (en) * 2013-08-06 2018-09-26 Эксосам Дайэгностикс, Инк. Urine biomarker cohorts, gene expression signatures and methods of use thereof
EP3214444A1 (en) * 2016-03-04 2017-09-06 AIT Austrian Institute of Technology GmbH Prostate cancer diagnostic method and means

Also Published As

Publication number Publication date
US20230298695A1 (en) 2023-09-21
WO2019165021A1 (en) 2019-08-29
CN112673115A (en) 2021-04-16
AU2019224025A1 (en) 2020-09-10
CA3091647A1 (en) 2019-08-29
US11410748B2 (en) 2022-08-09
EP3755816A1 (en) 2020-12-30
IL276748A (en) 2020-10-29
BR112020016989A2 (en) 2020-12-29
JP2021514624A (en) 2021-06-17
US20190259471A1 (en) 2019-08-22
KR20200123450A (en) 2020-10-29
MX2020008702A (en) 2020-09-25

Similar Documents

Publication Publication Date Title
IL272470A (en) Methods and materials for assessing and treating cancer
IL271888A (en) Therapeutic and diagnostic methods for cancer
IL262225A (en) Methods for monitoring and treating cancer
IL268396A (en) Diagnostic and therapeutic methods for cancer
IL274246A (en) Diagnostic and therapeutic methods for cancer
IL276748A (en) Methods for prostate cancer detection and treatment
IL262223A (en) Methods for monitoring and treating cancer
IL273071A (en) Diagnostic and therapeutic methods for cancer
EP3891294A4 (en) Methods for treating castration-resistant and castration- sensitive prostate cancer
IL264443A (en) Methods of treating prostate cancer
EP3615056A4 (en) Methods and agents for the detection and treatment of cancer
IL263562A (en) Methods and compositions for prostate cancer diagnosis and treatment
EP3589659A4 (en) Compounds and methods for treating cancer
IL276089A (en) Methods for colon cancer detection and treatment monitoring
SG11202001796SA (en) Bacteria for targeting tumors and treating cancer
IL282478A (en) Materials and methods for treating cancer
ZA202006008B (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
IL280830A (en) Conjugates for use in methods of treating cancer
EP3697767A4 (en) Compounds and methods for treating cancer
GB2575389B (en) System and method for prostate cancer treatment under local anesthesia
IL265675A (en) Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer
EP3468564A4 (en) Methods for diagnosing and treating metastatic cancer
IL274714A (en) Methods and materials for assessing and treating cancer
EP3675893A4 (en) Methods for treating and diagnosing metastatic liver cancer
GB201819026D0 (en) Means and methods for treating cancer